My watch list
my.bionity.com  

my.bionity.com

With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

ProSavin



ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's Disease. It is administered to the striatum in the brain, inducing production of dopamine.[1]

It is manufactured by Oxford BioMedica, who plan to start European Phase I and Phase II clinical trials in 2007. Animal trials have been a success, with dopamine levels restored without the side effects associated with other current treatments for Parkinson's.[2]

Mechanism of Action

Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[3]

See also

References

  1. ^ Oxford BioMedica. Drug Information Page. Retrieved on March 29, 2007.
  2. ^ Daily Telegraph. Investor Information. Retrieved on March 29, 2007.
  3. ^ Oxford BioMedica . Drug Advanced Information Page. Retrieved on April 5, 2007.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "ProSavin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE